Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VACCIMIL-ZOSTER: Shingrix Immunogenicity in RA Patients on JAK Inhibitors
NCT03886038Phase 4Completed
- Sponsor
- Region Skåne
- Start
- Mar 2019
- Primary completion
- Feb 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of Zoster vaccine recombinant in herpes zoster (HZ) (2 arms), sponsored by Region Skåne. Primary endpoints: Differences in serological response (gE antibody levels) and Differences in T cells response. Started Mar 2019; status: completed.
02
Drugs
Zoster vaccine recombinant
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT03886038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03886038.